Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.
Twist Bioscience Corporation (TWST) is a leader in synthetic DNA production, utilizing a proprietary semiconductor-based platform to drive innovations across biotechnology and healthcare. This page provides investors and industry professionals with timely, accurate updates on TWST's strategic developments and operational milestones.
Access consolidated press releases and news covering earnings announcements, product launches, research breakthroughs, and partnerships. Our curated updates ensure you stay informed about TWST's advancements in gene synthesis, high-throughput manufacturing, and applications in precision medicine.
Key content includes quarterly financial results, regulatory filings, technology patents, and collaborations with academic or industry partners. All materials are sourced directly from verified company communications to maintain factual integrity.
Bookmark this page for streamlined access to TWST's evolving role in synthetic biology. Check regularly for critical updates impacting market positioning and technological leadership in DNA synthesis.
Twist Bioscience Corporation (NASDAQ: TWST) has launched the AsterExome panel, a tool designed to enhance oncology research through comprehensive whole exome sequencing (WES). This panel covers 620 cancer-associated genes, integrated into the AVATAR sequencing program by Aster Insights. It aims to improve the efficiency and accuracy of cancer research, identifying copy number variations and somatic mutations that standard panels may overlook. The collaboration with Aster Insights brings together extensive clinicogenomic data, accelerating the discovery of personalized therapies. This innovation leverages Twist’s proprietary DNA synthesis technology, positioning the company favorably in the competitive oncology research landscape.
Twist Bioscience Corporation (NASDAQ: TWST) has announced a collaboration with Astellas Pharma Inc. to license a suite of VHH antibody libraries aimed at drug discovery and development. This partnership includes three agreements over five years. Twist will receive an upfront payment, annual maintenance fees, and milestone-related payments, potentially extending to royalties on product sales. The collaboration highlights Twist's capacity to support customer needs in pipeline development through its innovative antibody solutions. Twist's VHH libraries can target a wide range of proteins and are designed for high specificity and binding affinity, which improves therapeutic development for diseases like cancer and autoimmune disorders.
FAQ
What is the current stock price of Twist Bioscience (TWST)?
What is the market cap of Twist Bioscience (TWST)?
